Ratings by BMO Capital (Matthew Luchini)
Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
3/18/2022 | Replimune Group | REPL | Maintain | Outperform (Outperform) |
|
Details | ||
11/4/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
10/21/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
10/20/2021 | Jasper Therapeutics | JSPR | New Coverage | Outperform (N/A) |
13.35 (21.34) |
59.85% | Details | |
10/19/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
9/20/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
9/20/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
9/16/2021 | NGM Biopharmaceuticals | NGM | Maintain | Outperform (N/A) |
|
Details | ||
9/10/2021 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
8/9/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
8/6/2021 | Replimune Group | REPL | Maintain | Outperform (N/A) |
|
Details | ||
8/6/2021 | Madrigal Pharmaceuticals | MDGL | Upgrade | Outperform (Market Perform) |
84.58 (192.54) |
127.64% | Details | |
8/6/2021 | TCR2 Therapeutics | TCRR | Maintain | Outperform (N/A) |
|
Details | ||
8/5/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
8/5/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
7/30/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (N/A) |
|
Details | ||
7/30/2021 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
7/22/2021 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
6/21/2021 | C4 Therapeutics | CCCC | Maintain | Outperform (N/A) |
|
Details | ||
5/24/2021 | NGM Biopharmaceuticals | NGM | Maintain | Outperform (N/A) |
|
Details | ||
4/20/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
3/31/2021 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
58.19 (31.74) |
-45.45% | Details | |
3/31/2021 | C4 Therapeutics | CCCC | New Coverage | Outperform (N/A) |
33.32 (6.20) |
-81.39% | Details | |
3/29/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
3/9/2021 | Decibel Therapeutics Inc | DBTX | New Coverage | Outperform (N/A) |
14.68 (4.91) |
-66.55% | Details | |
3/1/2021 | Kodiak Sciences Inc. | KOD | Maintain | Market Perform (N/A) |
|
Details | ||
2/26/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (Market Perform) |
|
Details | ||
2/26/2021 | Madrigal Pharmaceuticals | MDGL | Maintain | Market Perform (Market Perform) |
|
Details | ||
2/24/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
2/16/2021 | bluebird bio | BLUE | Maintain | Market Perform (N/A) |
|
Details | ||
2/11/2021 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
2/5/2021 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
1/25/2021 | Kodiak Sciences Inc. | KOD | Downgrade | Market Perform (Outperform) |
158.02 (3.22) |
-97.96% | Details | |
1/25/2021 | Regeneron Pharma | REGN | Upgrade | Outperform (Market Perform) |
535.48 (641.83) |
19.86% | Details | |
1/12/2021 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
1/7/2021 | Evelo Biosciences Inc | EVLO | Maintain | Outperform (N/A) |
|
Details | ||
12/14/2020 | Alexion Pharmaceuticals | ALXN | Downgrade | Market Perform (Outperform) |
118.87 (182.01) |
53.12% | Details | |
11/12/2020 | Kodiak Sciences Inc. | KOD | Maintain | Outperform (N/A) |
|
Details | ||
11/10/2020 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (N/A) |
|
Details | ||
11/6/2020 | Madrigal Pharmaceuticals | MDGL | Maintain | Market Perform (N/A) |
|
Details | ||
11/6/2020 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
11/5/2020 | bluebird bio | BLUE | Downgrade | Market Perform (Outperform) |
54.55 (0.89) |
-98.37% | Details | |
10/29/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
10/29/2020 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
10/27/2020 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
10/23/2020 | Apellis Pharmaceuticals | APLS | Maintain | Outperform (N/A) |
|
Details | ||
10/8/2020 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (N/A) |
|
Details | ||
8/10/2020 | Intercept Pharmaceuticals | ICPT | Maintain | Market Perform (N/A) |
|
Details | ||
8/6/2020 | Madrigal Pharmaceuticals | MDGL | Maintain | Market Perform (N/A) |
|
Details | ||
8/6/2020 | Stealth BioTherapeutics | MITO | Maintain | Market Perform (N/A) |
|
Details | ||
6/29/2020 | Intercept Pharmaceuticals | ICPT | Downgrade | Market Perform (Outperform) |
77.49 (19.00) |
-75.48% | Details | |
6/5/2020 | Madrigal Pharmaceuticals | MDGL | New Coverage | Market Perform (N/A) |
110.32 (192.54) |
74.53% | Details | |
6/5/2020 | NGM Biopharmaceuticals | NGM | New Coverage | Outperform (N/A) |
20.40 (1.54) |
-92.45% | Details | |
6/5/2020 | Intercept Pharmaceuticals | ICPT | New Coverage | Outperform (N/A) |
76.67 (77.49) |
1.07% | Details | |
6/5/2020 | Viking Therapeutic | VKTX | New Coverage | Outperform (N/A) |
7.11 (67.27) |
846.13% | Details | |
5/21/2020 | Inflarx NV | IFRX | Maintain | Market Perform (N/A) |
|
Details | ||
5/7/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
5/6/2020 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
4/20/2020 | Gilead Sciences | GILD | Downgrade | Market Perform (Outperform) |
76.54 (65.74) |
-14.11% | Details | |
4/13/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
3/31/2020 | Kodiak Sciences Inc. | KOD | New Coverage | Outperform (N/A) |
47.84 (3.22) |
-93.27% | Details | |
3/31/2020 | Apellis Pharmaceuticals | APLS | New Coverage | Outperform (N/A) |
26.26 (47.76) |
81.87% | Details | |
3/27/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
3/9/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
2/26/2020 | Gamida Cell Ltd. | GMDA | Maintain | Outperform (N/A) |
|
Details | ||
2/19/2020 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
2/13/2020 | Evelo Biosciences Inc | EVLO | Maintain | Outperform (N/A) |
|
Details | ||
2/5/2020 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
1/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
1/30/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
1/9/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
12/20/2019 | Stealth BioTherapeutics | MITO | Downgrade | Market Perform (Outperform) |
13.70 (0.32) |
-97.66% | Details | |
11/6/2019 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
11/5/2019 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
10/25/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
10/10/2019 | Ra Pharma | RARX | Downgrade | Market Perform (Outperform) |
22.69 (48.00) |
111.55% | Details | |
10/8/2019 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
9/27/2019 | Applied Genetic Technologies Corp. | AGTC | Upgrade | Outperform (Market Perform) |
3.78 (0.39) |
-89.68% | Details | |
9/16/2019 | Alder Biopharm | ALDR | Downgrade | Market Perform (Outperform) |
10.06 (18.88) |
87.67% | Details | |
9/12/2019 | Alexion Pharmaceuticals | ALXN | New Coverage | Outperform (N/A) |
109.60 (182.01) |
66.07% | Details | |
8/15/2019 | Inflarx NV | IFRX | Maintain | Market Perform (N/A) |
|
Details | ||
8/7/2019 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
8/7/2019 | Aeglea Biotherapeutics | AGLE | Maintain | Outperform (N/A) |
|
Details | ||
8/2/2019 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
7/31/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
7/15/2019 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
6/17/2019 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
6/5/2019 | Inflarx NV | IFRX | Downgrade | Market Perform (Outperform) |
37.29 (1.29) |
-96.54% | Details | |
5/8/2019 | Audentes Therapeutics | BOLD | Maintain | Outperform (N/A) |
|
Details | ||
5/3/2019 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
4/24/2019 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
3/15/2019 | Gilead Sciences | GILD | New Coverage | Outperform (N/A) |
65.75 (65.74) |
-0.02% | Details | |
3/12/2019 | Stealth BioTherapeutics | MITO | New Coverage | Outperform (N/A) |
16.81 (13.70) |
-18.5% | Details | |
3/8/2019 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
3/5/2019 | Nightstar Therapeutics | NITE | Downgrade | Market Perform (Outperform) |
15.16 (25.41) |
67.61% | Details | |
2/25/2019 | Spark Therapeutics | ONCE | Maintain | Market Perform (N/A) |
|
Details | ||
2/19/2019 | Spark Therapeutics | ONCE | Maintain | Market Perform (N/A) |
|
Details | ||
12/13/2018 | Applied Genetic Technologies Corp. | AGTC | Downgrade | Market Perform (Outperform) |
6.11 (3.78) |
-38.13% | Details | |
12/10/2018 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
11/21/2018 | Gamida Cell Ltd. | GMDA | New Coverage | Outperform (N/A) |
9.80 (0.03) |
-99.69% | Details | |
11/8/2018 | Applied Genetic Technologies Corp. | AGTC | Maintain | Outperform (N/A) |
|
Details | ||
11/8/2018 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
11/6/2018 | Spark Therapeutics | ONCE | Maintain | Market Perform (N/A) |
|
Details | ||
10/22/2018 | Entasis Therapeutics | ETTX | New Coverage | Outperform (N/A) |
7.44 (2.19) |
-70.56% | Details | |
9/24/2018 | Nightstar Therapeutics | NITE | Maintain | Outperform (N/A) |
|
Details | ||
8/15/2018 | aTyr Pharma | LIFE | Maintain | Market Perform (N/A) |
|
Details |